ORMP - Oramed subsidiary to start clinical trials for its oral COVID-19 vaccine candidate

ACELYA AKSUNKUR/iStock via Getty Images Announcing updates of its majority-owned company Oravax Medical, Oramed Pharmaceuticals (ORMP) said clinical trials for the unit’s oral COVID-19 vaccine would get underway first in Israel and then in additional sites globally. The study protocol has already been approved by Institutional Review Board ((IRB)) at Ichilov Hospital in Tel Aviv, Israel and the company is waiting for the approval from Israeli Ministry of Health. GMP manufacturing of the vaccine which is being developed as a booster shot as well as a standalone vaccine has already commenced, Oramed added in the statement. Oravax claims ownership to a virus-like particle ((VLP)) vaccine technology aimed at three surface proteins of the SARS CoV-2 virus. "Our vaccine is a particularly strong candidate against the evolving COVID-19 virus due to its unique targeting of three proteins rather than one,” noted Nadav Kidron, CEO of Oramed.

For further details see:

Oramed subsidiary to start clinical trials for its oral COVID-19 vaccine candidate